Biogen (BIIB) Stock
Established biotech company treating brain and nerve conditions. Here's the price, business snapshot, and what's worth knowing about Biogen in September 2026.
Biogen Inc is a US-based biotechnology company focused on treatments for neurological and neurodegenerative conditions. Investors should know the company mixes mature revenue-generating drugs for multiple sclerosis and spinal muscular atrophy with a high-profile and sometimes volatile research pipeline. Biogen’s market capitalisation is around $21.44B, which reflects both its commercial products and the market’s view of future approvals and patent timelines. Key drivers include clinical trial results, regulatory decisions, patent expiries and partnerships; these events can move the share price substantially. There is also reputational and regulatory risk following past controversy over Alzheimer’s therapy approvals. Biogen may appeal to investors who want exposure to neuroscience-focused biotech, but suitability depends on risk tolerance, investment horizon and portfolio diversification. This is general educational information only and not personalised investment advice — consider seeking independent financial advice and review the company’s latest filings before making decisions.
Why It’s Moving
Biogen’s Alzheimer’s launch progress and late-stage pipeline put its growth reset back in focus.
- Japan approved the once-weekly, self-administered LEQEMBI Pen on September 18, giving Biogen and Eisai a more convenient Alzheimer’s treatment option that could improve access beyond infusion centers.
- New Phase 3 EMPAVELI data showed a 75% relative reduction in proteinuria among adolescents with C3G or primary IC-MPGN, reinforcing Biogen’s expansion into kidney disease and rare-disease markets.
- At a September 14 healthcare conference, management outlined 10 Phase 3 programs approaching readouts and potential launches across five molecules, while acknowledging that declining legacy neuroscience products remain a near-term drag.
Biogen’s Alzheimer’s launch progress and late-stage pipeline put its growth reset back in focus.
- Japan approved the once-weekly, self-administered LEQEMBI Pen on September 18, giving Biogen and Eisai a more convenient Alzheimer’s treatment option that could improve access beyond infusion centers.
- New Phase 3 EMPAVELI data showed a 75% relative reduction in proteinuria among adolescents with C3G or primary IC-MPGN, reinforcing Biogen’s expansion into kidney disease and rare-disease markets.
- At a September 14 healthcare conference, management outlined 10 Phase 3 programs approaching readouts and potential launches across five molecules, while acknowledging that declining legacy neuroscience products remain a near-term drag.
Sixth Month Growth Performance
When is the next earnings date for BIOGEN INC (BIIB)?
Biogen (BIIB) is scheduled to report third-quarter 2026 financial results on October 28, 2026, before the market opens. This is a confirmed company-announced date rather than a purely historical estimate. The report will cover the quarter ending September 30, 2026.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biogen's stock with a target price of $240.57, indicating potential growth.
Financial Health
Biogen is generating strong revenue and profit margins, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Revenue and Pipeline
Biogen balances established drug sales with pipeline candidates; revenues can provide stability while trial readouts drive outlook, though results may be unpredictable.
Regulatory Catalysts
Regulatory decisions and trial outcomes are key value drivers — positive news can boost sentiment, but setbacks can quickly reverse gains.
Industry Dynamics
Competition, patent lifecycles and pricing pressure shape long-term prospects; consider diversification and risk tolerance before exposure, as biotech can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
